Drug Name
Antipsychotics/Antidepressants
|Drug Name |Class |MOA |Toxicity/Side fx |Clinical Use / Notes |
|Antipsychotic Agents |
|Promazine |Phenothiazines |Class 1 dopamine antagonist (CNS); Acts |Antihistamine (sedative) effects; Anticholinergic effects;|Neuroleptic (antipsychotic); originally used for |
| | |primarily at D2 receptors |Extrapyramidal effects: acute = dystonia, akathisia, |prolonged sedative effects |
| | | |parkinsonism; chronic = tardive dyskinesia esp. in facial | |
| | | |muscles; D2 receptor supersensitivity with chronic |Tolerance may develop to sedative effects. |
| | | |blockade; amenorrhea; orthostatic hypotension due to | |
| | | |α1-adrenergic blocking | |
|Chlorpromazine |Phenothiazines |Same as promazine; Chloride addition |Similar to promazine |Neuroleptic (antipsychotic); |
|(Thorazine®) | |(R2) makes more potent than promazine. | |Anti-emetic (not for motion-sickness); |
|Thioridazine |Phenothiazines |Same as promazine; R1 sub. of piperidine|Similar to promazine, but fewer sedative / extrapyramidal |Neuroleptic (antipsychotic); |
| | |ring ↓’s sedative and extrapyramidal |effects than above. | |
| | |effects. | | |
|Fluphenazine |Phenothiazines |Same as promazine; R1 piperazine ring |Reduced sedative and anticholinergic effects, but ↑ |Neuroleptic (antipsychotic) – usually reserved |
| | |plus R2 –CF3 group makes it most potent |extrapyramidal effects, |for severe or acute psychotic illness (Injectable|
| | |antipsychotic drug |Neuroleptic malignant syndrome: widespread, sustained |form available) |
| | | |muscle contractions, fluctuating consciousness and | |
| | | |autonomic abnormalities | |
Dr. Foster – 2/19/02
|Drug Name |Class |MOA |Toxicity/Side fx |Clinical Use / Notes |
|Haloperidol |Butyrophenones |Same as promazine; |Reduced sedative and anticholinergic effects, but ↑ |Neuroleptic (antipsychotic); anti-emetic; |
|(Haldol®) | |Potent |extrapyramidal effects, |Injectable form available. |
| | | |Neuroleptic malignant syndrome | |
| | | |(as w/fluphenazine) | |
|Thiothixene |Thioxanthenes |Same as promazine; thioxanthenes |Similar to promazine |Neuroleptic (antipsychotic) |
| | |substitute a N for a C in the structure | | |
| | |– more potent than promazine | | |
|Clozapine |Dibenzodiazepines |D1 and D4 receptor antagonist and |Low risk for extrapyramidal effects; Agranulocytosis in |Atypical antipsychotic; |
| | |interacts with muscarinic, 5-HT2 and |~1% within the first several months of treatment; | |
| | |α1-adrenergic receptors; Low potency and|Significant anticholinergic properties; orthostatic |Preferentially blocks mesolimbic and mesocortical|
| | |relatively low affinity for D2 dopamine |hypotension and compensatory tachycardia due to |tracts (not nigrostriatal) |
| | |receptors. |α1-adrenergic blockade. | |
|Risperidone |Benzisoxazoles |Prominent antiserotonergic and |No extrapyramidal effects at low doses. |Atypical antipsychotic |
| | |antidopaminergic activity | | |
|Antidepressants |
|Drug Name |Class |MOA |Toxicity/Side fx |Clinical Use / Notes |
|Imipramine |Tricyclics / |Demethylation produces active |Sedative; anticholinergic; orthostatic hypotension; weight|Antidepressant |
| |dibenzazepines |metabolite: desipramine; |gain; | |
| | | |Overdose: akathisia, seizures, depressed respiration, coma|Drugs that ↑ liver metabolism ↓ effectiveness |
| | |Inhibits neuronal reuptake of NE |Drugs that ↓ binding to albumin (NSAIDS, phenytoin, |(barbiturates, cigarettes, anticonvulsants) |
| | | |scopolamine, phenothiazines) or ↓ liver metabolism | |
| | | |(neuroleptics, contraceptives) ↑ side effects; |Tricyclics should NEVER be abruptly stopped due |
| | | |Additive sedative effects w/EtOH, neuroleptics and |to possibly severe withdrawal symptoms |
| | | |antihistamines. | |
| | | |Severe CNS interaction with MAO inhibitors, adrenaline and| |
| | | |noradrenaline, ephedrine, isoproterenol | |
|Amitriptyline |Tricyclics / |Demethylation produces active |Same as imipramine; extreme sedative effects |Antidepressant |
| |dibenzocyclo-heptadienes |metabolite: nortriptyline; Inhibits | |See imipramine notes |
| | |neuronal reuptake of NE | | |
|Doxepin |Tricyclics / |Inhibits neuronal reuptake of NE |Same as imipramine |Antidepressant |
| |dibenzoxepines | | |See imipramine notes |
|Phenelzine and |MAO inhibitors |Irreversible inhibitor of monoamine |High risk of orthostatic hypotension; hepatotoxic; |Antidepressant |
|Tranylcypromine | |oxidase |OD: insomnia, agitation, convulsions; | |
| | | |Severe drug interactions: tricyclics, sympathomimetics, | |
| | | |foods containing pressor amines like tyramine (cheese, red| |
| | | |wine), caffeine | |
|Moclobemide |MAO inhibitors |Selective irreversible inhibitor of |See above |Antidepressant |
| | |monoamine oxidase A | | |
|Drug Name |Class |MOA |Toxicity/Side fx |Clinical Use / Notes |
|Selegiline |MAO inhibitors |Selective irreversible inhibitor of |See phenelzine |Antiparkinson’s drug |
| | |monoamine oxidase B | | |
|Fluoxetine |SSRI |Causes downregulation of presynaptic |GI upset; ↓ libido |Antidepressant and tx for OCD |
|(Prozac®) | |5-HT1D autoreceptors, facilitates |OD: “serotonin syndrome” = akathisia, muscle twitches, | |
| | |transmission |hyperreflexia, sweating as a prelude to coma | |
|Fluvoxamine, Paroxetine |SSRI’s |See above | |Antidepressants |
|(Paxil®) | | | | |
|Sertraline (Zoloft®) | | | | |
|Venlafaxine |SSRI / NERI | |Less sedative than other antidepressants |Antidepressant |
|(Effexor®) | | | | |
|Amoxapine |2nd-generation (atypical)|Similar to tricyclics but also blocks DA|Cardiac effects; antimuscarinic; some sedative fx; |Antipsychotic/ Antidepressant |
| |antidepressants |receptors |extrapyramidal symptoms, amenorrhea | |
|Trazodone |2nd-generation (atypical)|Weakly inhibits 5-HT uptake, antagonist |Sedative, but less anticholinergic; less sexual |Antidepressant |
| |antidepressants |of 5-HT2 receptors and partial agonist |dysfunction, but priapism possible | |
| | |of 5-HT1A receptors | | |
|Bupropion |2nd-generation (atypical)|Inhibits DA uptake |Seizures, insomnia, psychosis |Anticraving drug for smokers |
|(Wellbutrin®, Zyban®) |antidepressants | | | |
|Drugs for Bipolar Disorder |
|Lithium salts | |Competes at cellular sites with Na+, K+,|GI irritation, goiter, rashes |DOC for recurrent bipolar affective disorder |
| | |Ca++ and Mg++; may interfere with |Low toxicity: apathy, lethargy, weakness, nausea; Med. | |
| | |monoamine neurotransmitters |toxicity: tremor, slurred speech, unsteady gait, | |
| | | |confusion; Severe toxicity: seizure, coma, | |
| | | |cardiovascular collapse | |
|Carbamazepine | | | |Anticonvulsant used for bipolar if Lithium |
| | | | |intolerance or incomplete protection from |
| | | | |recurrence |
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related searches
- sure jell drug test
- baking soda drug detox
- how does certo work for drug test
- me and name or name and i
- name and i vs name and me
- brand name drug generic equivalent
- name and i or name and myself
- name and i or name and me
- last name first name format
- drug induced lupus drug list
- drug to drug interaction examples
- full name generator with the name full